Peripartum cardiomyopathy (PPCM) is a rare cardiac disorder associated with high rates of mortality that occurs during the peripartum period. PPCM is recognized as a distinct entity, separate from preexisting cardiomyopathies that are worsened by the stressors of pregnancy. To date, its etiology is unknown, although several theories are under investigation in an effort to provide more information regarding available treatment options. A multidisciplinary review of PPCM held by the National Heart, Lung, and Blood Institute, in conjunction with the Office of Rare Disease of the National Institutes of Health, in April 1997 reviewed the current knowledge and developed recommendations for areas of further research and education about PPCM. Since then, there have been some promising research testing hypotheses regarding the etiology of PPCM and advancements in possible treatment options. However, despite these efforts, knowledge and treatment recommendations about PPCM are still generally unchanged, whereas mortality rates remain high. This article attempts to provide an updated, comprehensive review about PPCM and draw attention to areas in need of further research. P eripartum cardiomyopathy (PPCM) is a rare cardiac disorder that occurs during the peripartum period. The relationship between heart failure and pregnancy was first described in the 1870s by Virchow and Porack who noted myocardial degeneration in patients who died in the postpartum period. However, it was not until 1937 that Gouley et al 1 identified the cause of heart failure as a dilated cardiomyopathy, which was distinct from a preexisting cardiomyopathy worsened by the stressors of pregnancy. An autopsy series revealed areas of necrosis and fibrosis in focal areas that were not seen in myocardium after a myocardial infarction. Since then, PPCM has been recognized as a distinct entity.
INCIDENCE
In the United States, the incidence of PPCM ranges from one in 3000 to one in 15,000 pregnancies. In the United States, it is estimated that 250 to 1350 women per approximately 4 million deliveries will have PPCM. 2 The exact incidence is unknown because data comparing the incidence of the condition with age-matched nonpregnant women do not exist. The wide variation observed is most likely the result of geographic differences and differences in reporting patterns. 2 Mortality rates range anywhere between 9% and 56%, 3, 4 and most of the deaths have been reported to occur within the first 3 postpartum months. Causes of mortality often include heart failure, arrhythmias, or embolic events. Sudden death has been reported to occur in 50% of patients. 4 Mortality rates associated with embolic events alone can be as high as 30%. Risk factors for PPCM include multiparity, twin gestation, use of tocolytic therapy, preeclampsia, and black race. A study by Whitehead et al identified a 6-fold excess risk of death from cardiomyopathy (70% PPCM and 30% resulting from other causes) among black women. 5 Although black women are at increased risk, it is unclear whether race is an independent risk factor; the greater incidence of hypertension in pregnancy in blacks may influence these findings. 6 In April 1997, the National Heart, Lung, and Blood Institute (NHLBI), in conjunction with the Office of Rare Disease of the National Institutes of Health, held a multidisciplinary review of PPCM in an effort to review current information and develop recommendations for further research and education. The workshop stressed the importance of defining PPCM based on 4 criteria: 1) development of cardiac failure in the last month of pregnancy or within 5 months after delivery, 2) absence of a demonstrable cause for the cardiac failure, 3) absence of demonstrable heart disease before the last month of pregnancy, and 4) documented systolic dysfunction ( Table 1 ). The timing stipulation serves to exclude preexisting cardiac problems that may have become unmasked by the increased hemodynamic burden of normal pregnancy. 3 categories: 1) infectious, 2) immunologic, 3) nutritional, 4) drug-induced, and 5) familial.
Infectious
Evidence exists to support the hypothesis of myocarditis as an etiology for PPCM. One study found the prevalence of myocarditis to be as high as 62% (26 of 42 patients) based on histologic findings of endomyocardial biopsy 7 ; of the 62% of patients in this study, 45% (19 of 42 patients) had histologic myocarditis and 17% (7 of 42 patients) had histologic borderline myocarditis. A definite relationship between pregnancy and myocarditis proven by endomyocardial biopsy has been established by multiple studies and is well known. However, data regarding the prevalence of myocarditis in pregnancy has varied among studies. Variations are possibly the result of demographic differences, differences in the diagnostic criteria for PPCM or myocarditis, differences in the selection of patients for endomyocardial biopsy, or the timing of biopsy relative to onset of symptoms. Such variations can be attributed to difficulties performing endomyocardial biopsies and high rates of false-negatives resulting from the focal nature of the inflammatory infiltrates. 8 Even in patients with autopsy-proven myocarditis, premortem diagnosis by endomyocardial biopsy is only 63%. 8 A study by Felker et al demonstrated a prevalence of 62% in patients with diagnosed PPCM who underwent endomyocardial biopsy 7 ; however, the highest incidence of myocarditis in PPCM was found by Midei et al to be 76%. 9 In the subset of patients who have rapid, spontaneous improvement, it is recommended that endomyocardial biopsy be reserved for those patients who do not improve within 1 week of symptom onset. 8 A possible infectious etiology for PPCM is supported by experimental work demonstrating the susceptibility to viral infections in pregnant mice over nonpregnant mice; pregnant mice were found to be more susceptible to coxsackieviruses and echoviruses. Additionally, pregnant mice were found to have higher viral concentration in the myocardium when compared with levels found in nonpregnant mice. This susceptibility could be attributed to a blunted or muted immune response during pregnancy, thus resulting in unregulated viral replication. Moreover, the increased cardiac output seen in pregnancy was found to worsen the effect on the viral lesions. 10 In addition to increased susceptibility to coxsackieviruses and echoviruses, there is evidence to suggest an association of PPCM with chlamydia pneumonia infection. A study by Cénac et al identified a relationship between anti-Chlamydia pneumonia antibodies and PPCM in Niamey, Africa. 11 These investigators postulated that PPCM could be associated with persistent chlamydia pneumonia infection. This is the only known study recognizing the relationship between PPCM and chlamydia pneumonia infection, suggesting that further investigations are needed to validate this possible relationship.
Immunologic
Immunologic causes for PPCM stem from the abnormal immunologic activities that occur during pregnancy. Evidence of abnormal immunologic activities in pregnancy includes the presence of inflammatory cytokines. Studies have shown significant elevations of TNF-␣, IL-6, and Fas/APO-1 in patients with PPCM. 12 Some studies suggest that cardiomyopathy results from the development of antibodies that are formed during delivery. The fast degeneration of the uterus causes fragmentation of tropocollagen, which subsequently results in the release of actin, myosin, and other metabolites. 8 Antibodies formed against actin can crossreact with the myocardium and result in cardiomyopathy.
In other studies, antibodies to cardiac muscle proteins have been identified in patients with PPCM but not those with idiopathic cardiomyopathy. Antibody titers of adenine nucleotide translocator (ANT), branched chain alpha-keto acid dehydrogenase (BCKD), and myosin were significantly elevated when compared with those levels found in idiopathic cardiomyopathy. 10 Theories regarding an abnormal immune response to pregnancy stem from prior reports describing chimerism of the hematopoietic lineage cells from the fetus to the mother during pregnancy. 10 Some believe that fetal cells escape into the maternal circulation and into cardiac tissue. As a result of the natural immunosuppression of the mother during pregnancy, these cells are not rejected and remain weakly immunogenic. As a result, the mother recovers immune competency postpartum and the fetal cells in the cardiac tissue trigger a pathologic autoimmune response. 10 Other studies support the idea that PPCM is a form of autoimmune idiopathic dilated cardiomyopathy; however, it differs in that it is associated with unique sets of autoantibodies and cardiacspecific autoantigens, is more rapid in onset, and is exclusive to pregnant women. Moreover, the development of PPCM relies on the unique environment of pregnancy-hemodynamic stress, vasoactive hormones, and fetal microchimerism-to promote disease progression. 13
Nutrition
Nutritional disorders have been proposed to play a role in the development of PPCM because earlier studies demonstrate an increased incidence of PPCM in malnourished women. 3 However, because there have been no epidemiologic studies to validate such observations, the nutritional cause of the increase is questionable. The increased incidence of PPCM in Africa may be explained by nutritional differences in salt intake. In particular, there is a high prevalence of PPCM in Nigeria, which may be attributable to cultural practices during the postpartum period. According to tradition, during the first 40 postpartum days, Nigerian women are known to lie on heated mud beds and ingest kanwa, a form of dried lake salt. The high salt intake during this period can lead to a hemodynamic volume overload and could explain the increased incidence of PPCM. 14 Low selenium levels have been reported to be a possible risk factor for PPCM, and studies have found lower levels of selenium in patients with PPCM. A study performed in Haiti compared selenium levels and other micronutrients in mothers with PPCM and parity-matched control mothers. Mean selenium plasma levels of the patient with PPCM were comparable to control subjects. Moreover, the mean plasma level of selenium was substantially greater than that found in pediatric patients with Keshan cardiomyopathy. 15 There may be several mechanisms by which selenium could play a role in the pathogenesis of PPCM; low levels of selenium cause increased susceptibility to damage from viral infection or hypertension. However, there is no evidence that a selenium deficiency is a cause or risk factor for PPCM. 15 Relaxin is an ovarian hormone produced during pregnancy that has recently been found in the cardiac atria. Moreover, this hormone has both positive inotropic and chronotropic properties; thus, its presence could cause an excessive relaxation of the cardiac skeleton.
Drug-Induced
Some studies have associated PPCM with prolonged terbutaline therapy (4 of 15 women); however, it is unclear whether this agent induces cardiomyopathy or simply unmasks subclinical heart disease. 16 ␤-agonists may simply unmask clinical heart disease rather than inducing cardiomyopathy. 17 
Familial
There have been few reports of familial PPCM, which further suggests that it is a type of familial dilated cardiomyopathy that is unmasked with the stressors of pregnancy. 18 -20 
DIAGNOSIS AND MANAGEMENT
The challenge in recognizing and diagnosing PPCM exists as a result of the similarities between the symptoms of normal late pregnancy and early congestive heart failure. Patients in normal late pregnancy may have symptoms of dizziness, dyspnea, fatigue, or pedal edema, all of which are identical to those seen in patients with congestive heart failure. There are currently no specific clinical criteria for differentiating between the symptoms of late normal pregnancy and heart failure. As a result, the diagnosis of PPCM relies on a high index of suspicion in conjunction with the timing of symptoms and echocardiographic identification of new left ventricular systolic dysfunction, which includes depression of both fractional shortening and ejection fraction. 10 Without the suspicion of PPCM, symptoms leading to proper diagnosis can be insidious. As a result, numerous case reports have been published regarding various presentations that are not related to heart failure. Clinical presentation with arrhythmias and/or embolic events are not uncommon: cases of ventricular tachycardia, 21, 22 thromboembolism, 23 ventricular thrombi, 24 pulmonary embolism, 25 and even embolic myocardial infarction 26 have been reported.
TREATMENT
When a patient is diagnosed with PPCM, treatment should include the standard therapy for heart failure, which includes preload and afterload reduction and inotropic agents ( Tables 2 and 3 ). Therapies must be adjusted to account for potential teratogenic effects and for the excretion of drug or its metabolites during breast feeding after delivery. 27
Heart Failure
Diuretics, vasodilators, and digoxin comprise the standard heart failure therapy. Although angiotensin-converting enzyme (ACE) inhibitors are contraindicated during pregnancy as a result of their teratogenic effects, they should be included in postpartum treatment of PPCM. Before delivery, afterload reduction and vasodilation can be achieved with hydralazine and nitrates. Calcium channel blockers can be used for blood pressure regulation with the added benefit of decreasing uterine contractility; however, the majority of these agents have negative inotropic properties. 10 The excep- tion in this class of medication is amlodipine, a dihydropyridine calcium channel blocker, that has been shown to improve survival in nonischemic cardiomyopathy and may prove to be beneficial in patients with PPCM. 28 In the Prospective Randomized Amlodipine Survival Evaluation (PRAISE) trial, plasma levels of IL-6 were lowered after treatment with amlodipine, which suggests a potential role in the treatment of PPCM. 29 Preload reduction can be achieved with diuretics and nitrates; however, caution must be used to prevent dehydration, which can cause uterine hypoperfusion and fetal distress. Breast feeding with maternal use of loop diuretics such as furosemide, digoxin, warfarin, or heparin is safe. The experience with breast feeding while taking ACE inhibitors is more limited, but enalapril and captopril appear to be safe. 3 Inotropic agents such as digoxin should also be used as needed.
In patients who are acutely ill or highly symptomatic, intravascular agents can be used. Intravenous agents include nitroprusside and nitroglycerin for preload and afterload reduction in addition to inotropic agents such as dobutamine, dopamine, and milrinone. Intravenous drips should be titrated slowly as to maintain maternal intravascular euvolemia. Caution should be exercised when using nitroprusside as a result of possible fetal thiocyanate and cyanide accumulation.
The use of ␤-blockers in patients with congestive heart failure has been clinically beneficial; however, results are inconsistent regarding survival benefit. 30 Carvedilol is a va-sodilating ␤-blocker with ␣ 1 -blocking activity. The results of the U.S. Carvedilol Heart Failure program suggests that carvedilol may have potential benefit to reduce mortality; however, such effects have not been evaluated in the setting of PPCM. 28 Although ␤-blockers are not contraindicated in pregnancy, this class of drugs has been associated with some long-term adverse effects such as low-birth-weight babies. 8, 27, 31 A case of PPCM treated with levosimendan, a calcium sensitizer with additional vasodilation properties, has been reported. 32 Levosimendan, a new drug for treating acute heart failure, enhances cardiac contractility by improving the response of cardiac myofilaments to intracellular calcium and at the same time reduces cardiac workload by opening adenosine triphosphate-dependent potassium channels for dilation of blood vessels. 33, 34 Levosimendan does not increase intracellular calcium levels; therefore, it is less likely than other traditional inotropes to have deleterious effects on cardiac myocyte relaxation, cell survival, and arrhythmia induction. Additionally, case reports have shown increased stroke volume and decreased pulmonary capillary wedge pressure with use of levosimedan. 32 As a result of the long half-life of the metabolites of levosimedan, patients should be counseled to avoid breast feeding postpartum.
Anticoagulation
Anticoagulation should be considered for patients diagnosed with PPCM. However, as a result of the hypercoagulable state of pregnancy and the depressed ejection fraction in patients with PPCM, and the stasis and turbulent flow in the dilated heart, the risk of embolic events is high. Suspicion of a deep vein thrombosis (DVT) or pulmonary embolism should be investigated and prophylaxis should be considered in those at increased risk. However, both investigation and prophylaxis during pregnancy are not without risk and concern.
The Seventh American College of Chest Physicians (ACCP) Conference on Antithrombotic and Thrombolytic Therapy stated that anticoagulant therapy is indicated during pregnancy for the prevention and treatment of venous thromboembolism (VTE). 35 However, there is a lack of data regarding the efficacy of anticoagulants during pregnancy; thus, recommendations about their use during pregnancy are based on data from nonpregnant patients, case reports, and case series of pregnant patients. Heparin-related compounds such as low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) are the anticoagulants of choice during pregnancy based on safety reports and case studies. LMWH is at least as effective and safe as UFH in patients with acute proximal DVT and for DVT prophylaxis. Additionally, LMWH holds potential advantages over UFH when used during pregnancy; LMWH is associated with less heparininduced thrombocytopenia (HIT) and lower risk of heparininduced osteoporosis, has a longer plasma half-life, and thus has a more predictable dose response when compared with UFH, and can be administered once daily. Potential fetal complications of anticoagulation during pregnancy include teratogenicity and bleeding; however, because LMWH and UFH have been shown not to cross the placenta, these agents do not have the potential to cause fetal bleeding or teratogenicity, although bleeding at the uteroplacental junction is possible. In addition, heparin and LMWHs are not secreted into breast milk, and patients can safely breast feed postpartum despite anticoagulation treatment. Postpartum anticoagulation therapy with warfarin is also safe for the nursing mother, and reports have shown that warfarin does not induce an anticoagulant effect in the breast-fed infant. Unfortunately, the optimal management of anticoagulation during pregnancy is unknown and furthermore are unclear in patients with PPCM; however, trials of anticoagulant therapy are ongoing. 35 
Arrhythmias
Multiple cases of PPCM that present with arrhythmias have been reported. 21, 22 Arrhythmias should be treated according to standard protocol. However, class 3 (amiodarone) and class 4 (verapamil) antiarrhythmics should be avoided as a result of adverse effects on the fetus: fetal hypothyroidism and premature delivery, fetal bradycardia, heart block, and hypotension. 17
Immunosuppression
A role for immunosuppressive therapy in the treatment of PPCM is based on evidence that PPCM is the result of myocarditis. 36 In a study investigating the association of underlying causes and long-term survival in patients with cardiomyopathy, histologic evidence of myocarditis on endomyocardial biopsy was observed in 26 of 51 patients with PPCM. 37 Although further studies are needed to determine the role for immunosuppressive agents in the treatment of PPCM, recent studies have demonstrated promising results.
Pentoxifylline is a drug that has been demonstrated to inhibit proinflammatory cytokines and has beneficial effects on New York Heart Association (NYHA) functional class, left ventricular ejection fraction, and markers of apoptosis in patients with idiopathic dilated cardiomyopathy. The results of a clinical trial were reported on in which patients with PPCM were treated with pentoxifylline. A combined end point of poor outcome, defined as death, failure to improve left ventricular ejection fraction more than 10 absolute points, or functional class III or IV at latest follow up, occurred in 27% of patients treated with pentoxifylline and in 52% of those on usual therapy. 38 In patients with heart failure resulting from ischemic left ventricular dysfunction, treatment with pentoxifylline improved ejection fraction and reduced plasma markers of inflammation including TNF-␣, CRP, and Fas/ Apo-1. 39 The results of this study suggest that the addition of pentoxifylline to conventional treatment improves outcome in patients with PPCM. Improved ejection fraction in women with PPCM was also seen with the use of intravenous immune globulin. These women showed greater improvements in ejection fraction during early follow up than women who had conventional treatment. 40 Immunosuppressive therapy can be considered if an endomyocardial biopsy indicates the presence of myocarditis and if there is no improvement after 2 weeks of standard heart failure therapy. 10 Prospective blind studies are needed to define the exact role of immunosuppressive agents in the treatment of PPCM.
Antiapoptotic Agents
Studies investigating the role of apoptosis in heart failure demonstrate a possible role for antiapoptotic agents in the treatment of PPCM. In transgenic mice with overexpression of G␣q, a reduction in cardiac myocyte apoptosis by caspase inhibition improved both left ventricular function and survival. 41
Other Treatment Options
Nonpharmacologic treatments for patients with PPCM should include sodium restriction to less than 4 g per day, fluid restriction to less than 2 L per day, and a regimen of modest exercise once symptoms of heart failure are controlled. For those who fail to show improvement or who clinically deteriorate despite medical management, cardiac transplant is needed. 4 Intraaortic balloon pump or ventricular assist devices can be used as a bridge to cardiac transplant.
DELIVERY
Early delivery is not required in patients with PPCM; however, if medical management is unsuccessful and the patient shows clinical decompensation, then early delivery may be needed. Should medical treatment of heart failure be successful, then spontaneous vaginal delivery is not contraindicated. Caution should be used during the final stages of delivery; obstetricians may opt for the use of low-forceps or vacuum devices to assist delivery to avoid the exertion of pushing with increased ventricular work contributing to acute heart failure. In patients who do not respond well to medical therapy, induction of labor for vaginal delivery is acceptable. The mode of delivery should be assessed in collaboration with obstetricians, cardiologists, and anesthesiologists. Although vaginal deliveries are preferable to cesarean deliveries as a result of the reduced risk of endometritis, pulmonary embolism, and postoperative complications seen in cesarean deliveries, the cardiovascular benefit from prompt delivery is more important whether the delivery is vaginal or cesarean.
The anesthetic management of labor and delivery is challenging for patients with PPCM. As a result of the rarity of the clinical situation, guidelines for anesthetic management are not well defined. In cases of patients presenting with heart failure and requiring operative delivery, continuous spinal anesthesia (CSA) has been used successfully. CSA is a more reliable and rapidly titratable technique. CSA has minimal undesirable hemodynamic changes and is more hemodynamically stable than single doses of spinal anesthesia for cesarean section. 42 In addition, CSA causes lower drug concentrations within the maternal and fetal circulation. The disadvantages of CSA include the risk of postdural puncture headache and the cauda equina syndrome.
Many cases using combined spinal epidural anesthesia (CSEA) have been reported. [43] [44] [45] CSEA is preferred over epidural anesthesia as a result of lower failure rates. In addition, the use of CSEA showed better intraoperative patient satisfaction, anxiolysis, and postoperative pain scores. 45 Additionally, CSEA causes a lower incidence of hypotensive Case reports of intravenous remifentanil infusion have shown benefit in patients with PPCM. Remifentanil is a synthetic opioid that provides cardiovascular stability in highrisk patients. Remifentanil has a unique mode of metabolism by plasma and tissue esterases with a half-life of 3 to 4 minutes that is independent of the duration of infusion. The opioid properties allow control of the intraoperative stress response and allow for a more rapid recovery compared with other opioids. The short duration of action also decreases the risk of transplacental passage and subsequent neonatal depression. Case reports show that remifentanil demonstrates minimal central nervous system and respiratory depression in the fetus. 46 
Postpartum Management
The postpartum management of patients with PPCM should continue with the standard therapy for heart failure: diuretics, vasodilators, and digoxin. Patients previously on hydralazine and nitrates can safely be placed on ACE inhibitors in the postpartum period. Patients with persistent systolic dysfunction should be maintained on vasodilators, nitrates, and diuretics as indicated and as tolerated.
PROGNOSIS
Prognosis is dependent on recovery of systolic function. Mortality from multiple small series has ranged from 7% to 50%, with half of the deaths occurring within 3 months of delivery. Demakis et al 6 divided a group of 27 women into 2 groups at 6 months based on the presence of normal heart size or cardiomegaly. Fourteen of 27 (52%) had resolution of cardiomegaly and none of these patients died of congestive heart failure. However, 11 of 13 (85%) patients with persistent cardiomegaly died of heart failure with an average survival of 4.7 years. If symptoms persist longer than 6 months, myocardial damage is most likely irreversible and the prognosis is grim. Lampert et al 47 reported an abnormal response to low-dose dobutamine in women with normal ventricular function at rest. Failure to mount a normal inotropic response to low-dose dobutamine is an indication of abnormal contractile reserve. This may render the women unable to meet the increased hemodynamic burden in a subsequent pregnancy. There are insufficient data to recommend dobutamine stress echo testing to risk stratify women, but it is an area for future study. 3 In studies comparing survivors with nonsurvivors, survivors had higher left ventricular ejection fractions (22.8% vs. 10.6%) and smaller left ventricular end diastolic diameters (5.8 vs. 0.9 cm) at the time of diagnosis. 4, 48 The risk of mortality can be lowered with better medical treatment and cardiac transplantation.
One study found that the prognosis of patients with PPCM when compared with other known causes of cardiomyopathy (doxorubicin therapy, infiltrative myocardial disease, HIV infection, ischemic heart disease, and idiopathic causes) was the most favorable. Additionally, PPCM was the only subgroup showing substantially better long-term survival rates than those with idiopathic cardiomyopathy. 37 Current data reveal that long-term survival is better than was historically reported. 4 Felker et al 7 showed that the prognosis for patients with PPCM is relatively good and has a low incidence of death (7%) or need for transplantation (7%) after more than 8 years of follow up. This improvement in long-term survival could reflect the improvements in the treatment of patients with heart failure or a change in the natural history of PPCM. 4 Another study showed anti-Chlamydia pneumonia antibodies to have prognostic value in patients with PPCM at the time of diagnosis; higher dilutions of the antibodies were associated with poorer prognosis. It was proposed that Chlamydia pneumoniae infections are more frequent and intense in patients who have more severe forms of PPCM. Additionally, the intensity of infection and the effects on the immune response of the patient is directly related to the cause of PPCM. 11 Other studies identified the ejection fraction at presentation to be the strongest predictor of outcome. 4, 12 Also, radiologic findings were associated with poorer prognosis; persistent cardiomegaly on chest x-ray was associated with a 85% mortality. 6
Future Pregnancies
The risk of recurrence with subsequent pregnancies is dependent on the total functional recovery of cardiac function. Future pregnancy is not recommended in women with persistent ventricular dysfunction for fear of an inability to tolerate the increased cardiovascular workload associated with pregnancy. A study by Sliwa et al 49 demonstrated a high mortality rate in patients with persistent left ventricular dysfunction after the first pregnancy. These patients also had elevated postpartum levels of TNF-␣ with the deterioration of left ventricular function. TNF-␣ levels measured at 1 month and 3 months postpartum after subsequent pregnancy were significantly elevated when compared with healthy agedmatched volunteers. In addition, TNF-␣ levels at 1 month (6.2 Ϯ 2.4 pg/mL) postpartum were also significantly elevated from those found at the onset of the subsequent pregnancy (2.4 Ϯ 1.1 pg/mL).
A study by Elkayam et al 50 investigated outcomes of 60 subsequent pregnancies from 44 women with PPCM. Twenty-eight women had normalized left ventricular function after their first pregnancy, whereas 16 women had persistent dysfunction. The women with persistent dysfunction had a higher percentage of heart failure symptoms (44% vs. 21%), a higher mortality (19% vs. 0%), a higher percentage of premature delivery (37% vs. 11%), and a higher percentage of therapeutic abortions (25% vs. 4%). Despite differences in deleterious fetal and maternal outcomes during subsequent pregnancy, outcomes were poor in both women with persistent left ventricular dysfunction and in women with normalized left ventricular function after initial pregnancy. 50 As a result of the potential unfavorable effect of PPCM on both fetal and maternal outcome, strong consideration should be given to avoiding additional pregnancies in these high-risk patients. 51 Despite normalization of left ventricular function, multiparity is a risk factor associated with PPCM. The risk of
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CARDIOMYOPATHY EARLY IN PREGNANCY
Although the criteria for PPCM has been well defined, there are situations in which cardiomyopathy is seen earlier in pregnancy. 4 It appears that the clinical presentation and outcome of patients with pregnancy-associated cardiomyopathy diagnosed early in pregnancy are similar to those of patients with traditional PPCM. These 2 conditions may represent a continuum of a spectrum of the same disease. 4
CONCLUSION
Since its recognition by Gouley et al in 1937, 1 PPCM to date is still considered to be a cardiomyopathy of unknown cause, and despite advances in the medical treatment of heart failure, the condition is still associated with significant mortality. The multidisciplinary workshop and review of PPCM conducted by Pearson et al 10 identified a need for an international registry to capture prospectively all women with PPCM. Such a registry will help to better document the incidence and prevalence estimates, the determination of risk factors, prognostic variables, ascertainment of cardiovascular risks for subsequent pregnancies, establishment of a centralized serum and tissue bank to help facilitate identification and cause of PPCM, and evaluation of therapeutic interventions. Although some efforts have been made to further our current knowledge of PPCM, 4 patients with PPCM are still in need of more definitive recommendations to decrease mortality.
